Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can develop after a person has had a bone marrow or stem cell transplant. In the disease, the host body comes under attack from the donated cells.

What is Graft Versus Host Disease (GVHD)?

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

High-impact clinical trial results to be presented at ASN Kidney Week 2023

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2023 November 1–November 5.

3 Nov 2023

Research breaks ground on new ways of treating blood disorders with gene therapy

Research from experts at Michigan Medicine, the Children's Hospital of Philadelphia and Penn Medicine is breaking ground on new ways of treating blood disorders, such as sickle cell anemia, through gene therapy.

9 Aug 2023

New gene editing approach could revolutionize the treatment of blood disorders

In a step forward in the development of genetic medicines, researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body.

27 Jul 2023

Experimental antibody treatment shows promise for preventing bone marrow transplant complication

An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children's Cancer and Blood Disorders Center and published today in Science Translational Medicine.

28 Jun 2023

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

UW researchers identify a target that may make bone marrow transplants safer and more effective

A bone marrow transplant can be a lifesaving treatment for people with relapsed blood cancers, but a potentially lethal complication known as graft-versus-host disease put limitations on this procedure.

24 Mar 2023

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Researchers examined the characteristics and outcomes of COVID-19 in immunocompromised patients.

29 Apr 2022

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

26 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Partially matched blood cells could help cure people with both cancer and HIV

Following the news that a third person has been cured of HIV, a Northwestern Medicine expert says partially matched blood cells could be used to cure many people living with both cancer and HIV.

21 Feb 2022

'Humanized' mouse model beats current approaches for finding the best organ donor

A "humanized" mouse model equipped with the immune system of a patient who needs an organ transplant beats current measures for identifying the best potential living donor, scientists report.

27 Aug 2021

Researchers conduct first-in-man clinical trial for new stem cell technology

Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore's first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore.

12 May 2021

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.

30 Apr 2021

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Leukemias are debilitating cancers of the hematopoietic or blood-forming cells of the bone marrow. Now, researchers at Tokyo Medical and Dental University describe an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein an antibody-drug conjugate (ADC) comprising a cytotoxic drug payload linked to an antibody that selectively targets specific cell lines effectively blocks malignant cell proliferation at source.

16 Apr 2021

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

In the treatment of leukemia, stem cell transplantation subsequent to chemotherapy and radiation can often engender severe adverse inflammatory reactions - especially in the skin or in the gut, since these so-called barrier organs are more frequently affected.

19 Nov 2020

New Independent Research Organization status awarded to Anthony Nolan and ANRI

Anthony Nolan and the Anthony Nolan Research Institute have a long tradition of supporting and engaging with researchers.

9 Nov 2020

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Today, the U.S. Food and Drug Administration announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over the next four years.

8 Oct 2020

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Researchers at UPMC Children's Hospital of Pittsburgh found that infusing umbilical cord blood - a readily available source of stem cells - safely and effectively treated 44 children born with various non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD) and an array of immune deficiencies.

14 Jul 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Graft Versus Host Disease

Overview

Types of Graft Versus Host Disease (GVHD)

Symptoms and Diagnosis of Graft Versus Host Disease (GVHD)

Treatment of Graft Versus Host Disease (GVHD)

Feature Articles

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

High-impact clinical trial results to be presented at ASN Kidney Week 2023

Research breaks ground on new ways of treating blood disorders with gene therapy

New gene editing approach could revolutionize the treatment of blood disorders

Experimental antibody treatment shows promise for preventing bone marrow transplant complication

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

UW researchers identify a target that may make bone marrow transplants safer and more effective

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Roswell Park experts to share latest advances in the treatment of blood-related cancers

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Partially matched blood cells could help cure people with both cancer and HIV

'Humanized' mouse model beats current approaches for finding the best organ donor

Researchers conduct first-in-man clinical trial for new stem cell technology

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

Researchers develop an effective strategy to fight against chronic myelomonocytic leukemia

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Immune mechanism responsible for adverse inflammatory reactions after stem cell transplant identified

New Independent Research Organization status awarded to Anthony Nolan and ANRI

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Umbilical cord blood safely and effectively treats children with rare genetic disorders

Ruxolitinib shows promise in severe COVID-19

From surviving to thriving: a framework for long-term success in people with HIV

Kevin Broadbelt

Michael Stryker

Graft Versus Host Disease

Overview

Feature Articles

Causes and Risk Factors of Graft Versus Host Disease (GVHD)

Preventing Graft Versus Host Disease (GVHD)

Research into Graft Versus Host Disease (GVHD)

Graft Versus Host Disease Research

Latest Graft Versus Host Disease News and Research

From surviving to thriving: a framework for long-term success in people with HIV

Kevin Broadbelt

Michael Stryker

Newsletters you may be interested in